In the European Union,<unk>  is indicated for use in conjunction with clobazam and valproate as adjunctive therapy of refractory generalized tonic-clonic seizures in people with severe myoclonic epilepsy in infancy (SMEI, Dravet's syndrome) whose seizures are not adequately controlled with clobazam and valproate. In the United States,<unk>  is indicated for the treatment of seizures associated with Dravet syndrome in people two years of age and older taking clobazam. There are no clinical data to support the use of<unk>  as monotherapy in Dravet syndrome. It is used in some countries as an add-on therapy with sodium valproate and clobazam for treating children with Dravet syndrome whose seizures are not adequately controlled. As of 2017, it was not known whether<unk>  remains useful as children become adolescents or adults.
Stiripentol
Mitapivat
Loteprednol
Nicorandil
Agomelatine
Vigabatrin
Bocasan
Avacopan